Evaluation Of New Imaging Approaches In Alzheimer'S Disease

Grant number: 509166 | Funding period: 2008 - 2010

Completed

Abstract

Alzheimer's disease is the most common age-related neurodegenerative disease, and the most common cause of dementia. It is estimated that 212,000 Australians suffer from dementia and this will rise to approximately 730,000 by 2050. Currently there are no definitive diagnostic methods for AD. The research proposed in this application describes the evaluation of a new imaging radiotracer that would be suitable for widespread non-invasive diagnosis of AD.

Related publications (4)

A beta imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study

Kevin T Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Narelle Langdon, Ana M Catafau, Andrew W Stephens, John Seibyl, Ludger M Dinkelborg, Cornelia B Reininger, Barbara Putz, Beate Rohde, Colin L Masters, Christopher C Rowe

2015-04-01

F-18-florbetaben A beta imaging in mild cognitive impairment

Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gael Chetelat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe

2013-01-01

In vitro characterization of [F-18]-florbetaben, an A beta imaging radiotracer

Michelle T Fodero-Tavoletti, Damian Brockschnieder, Victor L Villemagne, Lucas Martin, Andrea R Connor, Andrea Thiele, Mathias Berndt, Catriona A McLean, Sabine Krause, Christopher C Rowe, Colin L Masters, Ludger Dinkelborg, Thomas Dyrks, Roberto Cappai

2012-10-01

Comparison of C-11-PiB and F-18-florbetaben for A beta imaging in ageing and Alzheimer's disease

Victor L Villemagne, Rachel S Mulligan, Svetlana Pejoska, Kevin Ong, Gareth Jones, Graeme O'Keefe, J Gordon Chan, Kenneth Young, Henri Tochon-Danguy, Colin L Masters, Christopher C Rowe

2012-06-01